MARCH 7-12, 1997
Basic and Clinical Aspects of Breast Cancer
Chairpersons: J. Carl Barrett, Research Triangle Park, NC; Karen S.H. Antman, New York, NY; Mary-Claire King, Seattle, WA
Keystone Resort, Keystone, CO

APRIL 12-16, 1997
88th Annual Meeting
Chairperson: Frederick P. Li, Boston, MA
Co-Chairpersons: Clara Derber Bloomfield, Buffalo, NY; Stephen H. Friend, Seattle, WA
San Diego Convention Center, San Diego, CA

JUNE 7-11, 1997
Cancer of the Central Nervous System
Conference with Neurosurgery Joint Section on Tumors
Chairpersons: Peter McL. Black, Boston, MA; Webster K. Cavenee, La Jolla, CA
Loew's Coronado Bay Resort, San Diego, CA

SEPTEMBER 9-13, 1997
Molecular Genetics of Cancer
Conference with the European Association for Cancer Research
Chairpersons: Eric J. Stanbridge, Irvine, CA; Walter Bodmer, Oxford, England
Hertford College, Oxford, England

SEPTEMBER 26-30, 1997
Tumor Suppressor Genes
Chairpersons: Stephen H. Friend, Seattle, WA; Philip Branton, Montreal, Quebec, Canada
Victoria Conference Centre, Victoria, BC, Canada

OCTOBER 17-21, 1997
Gene Regulation in Differentiation and Development
Chairpersons: Robert Eisenman, Seattle, WA; Elaine V. Fuchs, Chicago, IL
The Sagamore Resort, Bolton Landing (Lake George), NY

DECEMBER 1997
Epigenetics of Cancer
Chairperson: Peter A. Jones, Los Angeles, CA
Location in Puerto Rico to be announced

JANUARY 9-13, 1998
Colorectal Cancer — Biology, Treatment, and Prevention
Joint Meeting with the American Society of Clinical Oncology
Chairpersons: Robert J. Mayer, Boston, MA; One Additional Chairperson to be announced
Renaissance Esmeralda Resort, Indian Wells (Palm Springs), CA

JANUARY 1998
Anglogenesis and Cancer
Chairpersons: Judah Folkman, Boston, MA; Michael Klagsbrun, Boston, MA
Location in Orlando, FL to be announced

FEBRUARY 16-21, 1998
Innovative Molecular Biology Approaches to the Prevention, Diagnosis, and Therapy of Cancer
Joint Meeting with the Japanese Cancer Association
Chairpersons: Edward Bresnick, Worcester, MA; Kaoru Abe, Tokyo, Japan
Maui Marriott Resort, Maui, HI

AACR members will receive brochures on the above conferences as soon as they are available. Nonmembers should call or write:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)
E-Mail: aacr@aacr.org

For regular updates to this list visit the AACR's Website, http://www.aacr.org
PROFESSOR AND CHAIR
DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY
DARTMOUTH MEDICAL SCHOOL

Applications are invited from researchers in the area of cancer biology for the position of Professor and Chair of the Department of Pharmacology and Toxicology at Dartmouth Medical School. The Department participates in the education of M.D., Ph.D., and M.D./Ph.D. students. Members of the faculty conduct research on a wide range of interdisciplinary topics including cancer biology, with a strong emphasis on cellular and molecular pharmacology (information available at http://www.dartmouth.edu/dms/pharmtox/). The faculty maintain research and academic ties to other departments at Dartmouth Medical School, the Norris Cotton Cancer Center, Dartmouth College, and the Veterans Administration Medical Center.

Applicants should have an active research program and a strong record of scientific and scholarly achievement commensurate with that expected of the holder of an endowed chair which will accompany this position. They should have a strong commitment to excellence in education, and have the leadership qualities necessary for developing the faculty and promoting the research and academic programs of the Department.

Letters of application, accompanied by a curriculum vitae, names and addresses of three references, and a summary of current research activities and support, should be sent to Pharmacology-Toxicology Search Committee, Office of the Dean, Dartmouth Medical School, Hanover, NH 03756.

Dartmouth College is an Affirmative Action/Equal Opportunity employer and encourages applications from women and members of minority groups.

CLINICAL TRIALS PROGRAM
PROSTATE CANCER INITIATIVE
OF THE
CANCER RESEARCH INSTITUTE

The Cancer Research Institute announces the availability of Clinical Research Seed Grants to support Phase I or Phase II trials. The Institute is planning to make individual grants in the amount of $150,000 over two years to support clinical research aimed at testing novel immunotherapies for advanced prostate cancer. The Cancer Research Institute does not provide funds for indirect costs. The deadline for receiving applications (including the clinical protocol) is April 15, 1997. The clinical research may be conducted in the United States or abroad, at nonprofit medical centers or hospitals.

For applications, please contact:
Ms. Lynne Harmer
Director of Grants Administration
Cancer Research Institute
681 Fifth Avenue
New York, NY 10022-4209
212-688-7515, FAX: 212-832-9376
or e-mail: cancerres@aol.com

AMERICAN CANCER SOCIETY
REQUEST FOR APPLICATIONS
HEALTH POLICY AND
OUTCOMES RESEARCH—
PROSTATE CANCER

The American Cancer Society is earmarking $3,000,000 in 1997 for Health Policy and Outcomes Research in Prostate Cancer. Application is open to independent investigators at any stage of their careers.

The first deadline is April 1, 1997. Subsequent deadlines will be October 15, 1997, and on those same dates through 1999. The grants will be for three years, up to $250,000 per year, including 25% indirect costs, and will be renewable as long as this remains a targeted priority area. Please contact the Office of Sponsored Programs at your institution after January 1, 1997, for a special RFA application form, or download from http://www.cancer.org.

Questions concerning this RFA should be directed to Dr. Ralph Vogler at (404) 329-7542 or Dr. Frank Baker at (404) 329-7795.

FACULTY LEVEL POSITIONS
IN GENETICS

The Southwest Foundation for Biomedical Research invites applications for two faculty-level positions in the Department of Genetics. One of the positions will require an interest in the genetics of cancer; the other position will require an interest in the molecular genetics of other research areas complementary to our existing programs. Ongoing research in the Department of Genetics includes genetic studies of common diseases (atherosclerosis, diabetes, obesity, hypertension, osteoporosis), gene mapping (nonhuman primates and marsupials), gene regulation during development, X-chromosome inactivation, and genetics of infectious diseases. Our existing program in cancer focuses on UV-induction of melanoma in experimental animal models. The successful candidates will be expected to develop strong independent research programs, and will have opportunities to collaborate in ongoing research. Unique resources available to our department include large human pedigrees, and large pedigreed colonies of nonhuman primates and marsupials. Ample opportunities exist for affiliations with local academic institutions. Applications are invited from scientists at any academic level. A doctoral level degree in a biological science is required. The positions present an excellent opportunity for creative scientists in an established genetics department. Please mail curriculum vitae, statement of research interests, and names, addresses, and telephone numbers of three references to: Director of Human Resources (632-CR), SFBR, P.O. Box 760549, San Antonio, Texas 78245-0549.

Equal Opportunity Employer.
AMERICAN CANCER SOCIETY
REQUEST FOR APPLICATIONS
NOVEL IDEAS IN PROSTATE CANCER CELL BIOLOGY

The American Cancer Society has earmarked $1.5 million in 1997 for Novel Ideas in Prostate Cancer Cell Biology. Application is open to independent investigators at any stage of their careers.

The first deadline for these applications is April 1, 1997. Subsequent deadlines will be October 15, 1997, and on those same dates through 1999. The grants awarded in response to this RFA will be for three years, up to $65,000 per year, including 25% indirect costs, and will be renewable as long as this remains a targeted priority area. Please contact the Office of Sponsored Programs at your institution after January 1, 1997, for a special RFA application form, or download from http://www.cancer.org.

Questions concerning this RFA should be directed to Dr. Peter Ove (404) 329-7552.

AMERICAN CANCER SOCIETY
REQUEST FOR APPLICATIONS
BEHAVIOR, PSYCHOSOCIAL, QUALITY OF LIFE—PROSTATE CANCER

The American Cancer Society is earmarking $3,000,000 in 1997 for Behavioral, Psychosocial, and Quality of Life Research relating to Prostate Cancer. Application is open to independent investigators at any stage of their careers.

The first deadline for these applications is April 1, 1997. Subsequent deadlines will be October 15, 1997, and on those same dates through 1999. The grants will be for three years, up to $250,000 per year, including 25% indirect costs, and will be renewable as long as this remains a targeted priority area. Please contact the Office of Sponsored Programs at your institution after January 1, 1997, for a special RFA application form, or download it from http://www.cancer.org.

Questions concerning this Request for Applications should be directed to Dr. Ralph Vogler (404) 329-7542 or Dr. Frank Baker (404) 329-7795.

Faculty Position Open
Biostatistics Core Director
Washington University Medical School

New joint faculty position with the Dept. of Biostatistics and the Washington University Cancer Center.

Primary Responsibility: To create and build a biostatistics core that provides design and analytical services to Cancer Center members for new and ongoing basic, clinical, and prevention and control research.

Qualifications: Candidates should have a Ph.D. in Biostatistics and minimum of 3 years experience in working with clinical trials.

Send curriculum vitae to:
Attn: Anita Harrison
Washington University Cancer Center
Box 8056, 4960 Children’s Place
St. Louis, MO 63110

Beatson International Cancer Conference
Co-sponsored by
ASSOCIATION FOR INTERNATIONAL CANCER RESEARCH

CANCER: FROM PEDIGREE TO PROTEIN
SUNDAY 6TH - WEDNESDAY 9TH JULY 1997
GLASGOW, SCOTLAND

KEYNOTE SPEAKER
W. Cavenee (USA)

SUSCEPTIBILITY
A. Bale (USA), A. Balmain (UK), S. Jackson (UK), J. Peto (UK), B. Ponder (UK)

CELL CYCLE
J. Bartek (DK), R. DePinho (USA), N. LaThangue (UK), J. Massagué (USA), C. Sherr (USA)

SUPPRESSOR GENE FUNCTION
W. Wright (USA), J. Holt (USA), K. Parkinson (UK), O. Pereira-Smith (USA), E. White (USA)

CELL BEHAVIOUR
R. Associ (USA), K. Burnöe (USA), K. Dane (DK), J. Collard (NL), E. Ruscel (USA)

TRANSLATIONAL RESEARCH
D. Lane (UK), C. Marshall (UK), F. McCormick (USA), B. Villeponteau (USA)

LATE BREAKING NEWS
Speakers to be invited shortly before the conference

for further information please contact:
TRICIA WHEELER
Conference Co-ordinator,
Beatson Institute for Cancer Research, Garscube Estate,
Switchback Road, Bearsden, Glasgow G61 1BD.
Tel: +44 141 942 0855 Fax: +44 141 942 6521
Web site: http://www.beatson.gla.ac.uk/beatson/conf
Deadline for registration APRIL 4th 1997
Time has been set aside for the presentation of 4-5 definitive reports of highly significant and timely findings in the field. Criteria for the selection of these presentations and instructions for submission of abstracts are as follows:

**INSTRUCTIONS FOR SUBMISSION OF LATE-BREAKING ABSTRACTS**

1. The work to be presented must be of major novelty and significance, *e.g.*, the characterization of a new gene in familial cancer or the discovery of a new diagnostic marker, and should not have been previously published in a peer-reviewed scientific journal or presented at a national meeting.

2. The abstract must be sponsored by an AACR member in good standing (dues paid for 1997).

3. Each member in good standing may sponsor only one abstract for this session whether or not he or she sponsored an abstract last November for the regular annual meeting program. If an associate member is the sponsor, the abstract must also be endorsed by an active or corresponding member in good standing. In this case, the endorser does not forfeit the opportunity to sponsor a late-breaking abstract.

4. Abstracts must be typed on one side of one sheet of white paper.

5. All text on the page must fit within an area 6 1/2" wide and 9" high (16.5 cm X 22.9 cm) with margins of at least 1" (2.5 cm) on the top, bottom, and sides of the page.

6. Each abstract must be accompanied by a covering letter from the sponsor explaining why the work is novel and significant enough to be considered for this late-breaking research session and certifying that the findings became available after the annual meeting abstract deadline of November 12, 1996. This letter must contain the sponsor's complete mailing address, FAX number, and E-mail address (if available) so that we can communicate the scheduling decision of the Program Committee.

7. Abstracts and covering letters must be received in the AACR Office by 5:00 p.m. Eastern Time on March 7, 1997. FAX transmissions are not acceptable. Carrying envelopes should be clearly marked "Late-Breaking Abstract," and should be addressed to American Association for Cancer Research, Public Ledger Building, Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483. If you wish to receive acknowledgment of receipt of your abstract, enclose a self-addressed post card with appropriate postage affixed. Accepted abstracts will not be published since they will be received after the *Proceedings of the American Association for Cancer Research* has been printed; however, they will be distributed at the session in San Diego.

8. A special subcommittee of the Program Committee appointed by President Louise C. Strong will select the papers to be presented. Presenters of accepted papers will be notified via FAX no later than March 24, 1997.
AACR SPECIAL CONFERENCE IN CANCER RESEARCH
Co-Sponsored by the Joint Section on Tumors of the American Association of
Neurological Surgeons and Congress of Neurological Surgeons

Cancer of the Central Nervous System

June 7-11, 1997
Loews Coronado Bay Resort
San Diego, CA

CONFERENCE CO-CHAIRPERSONS
Webster K. Cavenee / La Jolla, CA  Peter McL. Black / Boston, MA

PROGRAM COMMITTEE
William F. Chandler / Ann Arbor, MI  Mark D. Noble / Salt Lake City, UT
Joseph Plepmeier / New Haven, CT  Bernd R. Seizinger / Boston, MA
Jean Y. J. Wang / La Jolla, CA

CONFERENCE PROGRAM
Keynote Address
Charles B. Wilson / San Francisco, CA

Triumphs and Challenges of Present Diagnosis and Management
Catherine Dumas-Duport / Paris, France
Peter McL. Black / Boston, MA
Jay S. Loeffler / Boston, MA
Victor A. Levin / Houston, TX

Neurobiology and Developmental Biology
Fred H. Gage / La Jolla, CA
Mark D. Noble / Salt Lake City, UT

Genetic Predispositions to CNS Tumors
Jean Y. J. Wang / La Jolla, CA
Lawrence A. Donehower / Houston, TX
Eric C. Holland / Bethesda, MD
Nikolai Kley / Boston, MA

Molecular Genetics
David N. Louis / Boston, MA
Huei-Jen Su Huang / La Jolla, CA
Otmar D. Wiestler / Bonn, Germany

New Targets for Therapy
Mark L. Rosenblum / Detroit, MI
David Hockenberry / Seattle, WA
Jerry W. Shay / Dallas, TX
Kevin Webster / Princeton, NJ

Receptor Mediated Growth Control
Charles D. Stiles / Boston, MA
Webster K. Cavenee / La Jolla, CA
Lewis T. Williams / San Francisco, CA

Novel Therapies
Kendra O. Breskefield / Boston, MA
Jackson B. Gibbs / West Point, PA
Judah Folkman / Boston, MA
Frank McCormick / San Francisco, CA

ADDITIONAL SPEAKERS TO BE ANNOUNCED
Application Deadline: March 14, 1997

Information and Application Forms:
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)
E-mail: aacr@aacr.org
Website: http://www.aacr.org
Featured on the cover of this issue is Peter A. Jones, a Professor of Biochemistry, Molecular Biology, and Urology at the University of Southern California School of Medicine and Director of the USC/ Norris Comprehensive Cancer Center. Born in Cape Town, South Africa, Dr. Jones earned his B.S. from the University College of Rhodesia (London) in 1969, and his Ph.D. from the University of London in 1973. With the aid of numerous fellowships and awards, his postdoctoral studies resulted in receipt of the D.Sc. from the University of Zimbabwe in 1983. He was a National Institutes of Health postdoctoral fellow at the Childrens Hospital of Los Angeles from 1973 to 1975, and after several teaching and research appointments in South Africa, he returned to the U.S. in 1977 to join the USC, where he advanced from Assistant Professor of Pediatrics and Biochemistry (1977–1981) to full professorship in 1985. He was named Director of the USC/Norris Comprehensive Cancer Center in 1993, after serving as Associate Director for Basic Research for 9 years.

Dr. Jones’ major research efforts are in the area of gene mutations in cancer development, and he is an outstanding leader in the study of DNA methylation, exploring its role in controlling gene expression and in inducing a large proportion of cancer-causing mutations in humans. He introduced the use of 5-azacytidine as an agent to modify DNA methylation patterns and to induce the expression of silent genes (Cell, 20: 85, 1980). He was among the first to show that several hot spots for mutation in the p53 gene were sites for DNA methylation [Science (Washington, DC), 249: 1288, 1990], and he has studied the mechanism of mutation at 5-methylcytosine in greater detail. These experiments led to the demonstration that DNA methyltransferase itself is capable of acting as a cytosine deaminase, thus suggesting possible new routes to mutagenesis (Cell, 71: 1073, 1992).

Dr. Jones has led the development of translational research at the USC/Norris Comprehensive Cancer Center by initiating a program in bladder cancer in close cooperation with the Departments of Urology and Pathology. This research has identified the existence of putative tumor suppressor genes on chromosome 9, defined the role of the p53 gene in bladder cancer, and developed strong interactions with the Cancer Epidemiology Program, emphasizing the importance of mutational spectra in the p53 gene in understanding the genesis of human cancer (Cancer Res., 54: 784, 1994).

Dr. Jones’ research has been supported by peer-reviewed grants since 1978 and by an Outstanding Investigator Grant from the National Cancer Institute (NCI) since 1989. He has published 118 peer-reviewed papers and serves on the editorial boards of several prestigious journals, including Cancer Research, for which he has been an Associate Editor since 1983. He has also lectured widely throughout the world. He has served on many national committees and is a member of several professional societies, including the American Association for Cancer Research (AACR), of which he has been an active member since 1978. Dr. Jones has dedicated much time and energy to serving on AACR committees and fostering the society’s growth as a dynamic biomedical research organization. He served on the Board of Directors from 1989–1992, and he is currently a member of the Publications Committee (1994) and was recently appointed Chairperson of the Finance Committee (1996). He has also been Chairperson of the Special Memberships Committee (1993), the Local Arrangements Committee (1986), and the Biology Section of the Program Committee (1989).

Under Dr. Jones’ directorship, the USC/Norris Comprehensive Cancer Center utilizes its location in the large urban, multicultural environment of Los Angeles to study questions of racial and ethnic differences in cancer incidence and morbidity in its research programs. The development of the Center began in 1966 with the award of an NCI planning grant to the USC School of Medicine. The Center was inaugurated as the Los Angeles County-USC Cancer Center in mid-1971 and was awarded its first Core Grant and recognition as an NCI-designated comprehensive cancer center in 1973. The Center has two interdependent components: (a) the scientific research and educational activities that are conducted by University faculty and supported by the Center’s administration; and (b) the clinical care and patient and professional education that are provided in the Kenneth Norris Jr. Cancer Hospital, the LAC + USC Medical Center, and the Childrens Hospital of Los Angeles. The leadership structure of the Center has been deliberately designed to promote the concept of “centeredness” and to facilitate the development of interdisciplinary cancer research and treatment at USC. Under the direction of Dr. Jones, the research structure of the Center has been organized into five discipline-based and four disease-based programs: Gene Regulation; Cell Biology; Developmental Therapeutics and Clinical Trials; Cancer Epidemiology; Cancer Control Research; Genitourinary Cancer; Gastrointestinal Cancer; Breast Cancer; and Hematologic Malignancies/ Retroviral Disease. The disease-based programs have become very successful in providing foci for translational research.

The Center’s headquarters building (pictured to the left in bottom cover photo) on the Health Sciences Campus of the University was completed in 1983 with the aid of an $11.8 million NCI construction grant and includes basic research laboratories as well as inpatient and outpatient hospital facilities. The Center has recently opened a major addition to its headquarters building—the Dr. Norman Topping Tower (pictured to the right in the bottom cover photo). Eight years in the planning and construction, the Topping Tower is the embodiment of the Center’s mission: to reduce the burden of cancer morbidity and mortality in Southern California through the translation of research findings to patient care and education. The Topping Tower was also built with the assistance of a $1.2 million NCI construction grant. The new building houses greatly expanded outpatient facilities, two floors of research laboratories, offices for clinical faculty, and research and office space for faculty doing epidemiological and cancer control research.

Sidney Weinhouse

1 Photograph by Mario Lopez.